These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

424 related items for PubMed ID: 14739768

  • 21. Differential expression of matrix metalloproteinases and tissue inhibitors and extracellular matrix remodeling in aortic regurgitant hearts.
    Truter SL, Catanzaro DF, Supino PG, Gupta A, Carter J, Herrold EM, Dumlao TF, Borer JS.
    Cardiology; 2009; 113(3):161-8. PubMed ID: 19129699
    [Abstract] [Full Text] [Related]

  • 22. Membrane-associated matrix proteolysis and heart failure.
    Spinale FG, Janicki JS, Zile MR.
    Circ Res; 2013 Jan 04; 112(1):195-208. PubMed ID: 23287455
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Excessive activation of matrix metalloproteinases coincides with left ventricular remodeling during transition from hypertrophy to heart failure in hypertensive rats.
    Iwanaga Y, Aoyama T, Kihara Y, Onozawa Y, Yoneda T, Sasayama S.
    J Am Coll Cardiol; 2002 Apr 17; 39(8):1384-91. PubMed ID: 11955860
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. MMP induction and inhibition in myocardial infarction.
    Lindsey ML.
    Heart Fail Rev; 2004 Jan 17; 9(1):7-19. PubMed ID: 14739764
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Matrix metalloproteinases as input and output signals for post-myocardial infarction remodeling.
    Lindsey ML, Iyer RP, Jung M, DeLeon-Pennell KY, Ma Y.
    J Mol Cell Cardiol; 2016 Feb 17; 91():134-40. PubMed ID: 26721597
    [Abstract] [Full Text] [Related]

  • 31. Matrix metalloproteinase inhibition and the prevention of heart failure.
    Lee RT.
    Trends Cardiovasc Med; 2001 Jul 17; 11(5):202-5. PubMed ID: 11597832
    [Abstract] [Full Text] [Related]

  • 32. Matrix metalloproteinases in the progression of heart failure: potential therapeutic implications.
    Li YY, Feldman AM.
    Drugs; 2001 Jul 17; 61(9):1239-52. PubMed ID: 11511020
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. TIMP2 deficiency accelerates adverse post-myocardial infarction remodeling because of enhanced MT1-MMP activity despite lack of MMP2 activation.
    Kandalam V, Basu R, Abraham T, Wang X, Soloway PD, Jaworski DM, Oudit GY, Kassiri Z.
    Circ Res; 2010 Mar 05; 106(4):796-808. PubMed ID: 20056917
    [Abstract] [Full Text] [Related]

  • 37. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?
    Creemers EE, Cleutjens JP, Smits JF, Daemen MJ.
    Circ Res; 2001 Aug 03; 89(3):201-10. PubMed ID: 11485970
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Extracellular matrix remodeling attenuated after experimental postinfarct left ventricular aneurysm repair.
    Hsu CP, Huang CY, Wang JS, Sun PC, Shih CC.
    Ann Thorac Surg; 2008 Oct 03; 86(4):1243-9. PubMed ID: 18805169
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.